Press Release

LIXTE Announces Three-Way Clinical Trial Agreement With GSK and MD Anderson

September 20, 2023

Seattle – September 20, 2023 – Cooley advised Lixte Biotechnology, a clinical-stage pharmaceutical company focused on developing and commercializing new cancer therapies, on its clinical trial agreement with The University of Texas MD Anderson Cancer Center and GSK. Lawyers Alison Freeman-Gleason and Matthew Langer led the Cooley team advising LIXTE.

The clinical trial will assess whether adding LIXTE’s LB-100 to GSK’s programmed death receptor-1 (PD-1) blocking monoclonal antibody, dostarlimab, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma. The clinical trial is sponsored by and will be conducted at the MD Anderson Cancer Center and also will be open at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. LIXTE will provide LB-100, while GSK will provide dostarlimab and financial support for the clinical trial.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.